Close

FDA approves Aleors Diclofenac sodium topical solution

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Buyout of SpringWorks Brings Back Merck KGaA in the M&A Game

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally...

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The...

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing...

The US Food and Drug Administration (FDA) has granted tentative approval for Aleor Dermaceuticals’ Diclofenac sodium topical solution USP, 2% w / w to treat the pain of osteoarthritis of the knees.

Aleor is a 60:40 joint venture (JV) between Alembic and Orbicular Pharmaceutical Technologies. The JV was established in April 2016 to commercialise dermatology products globally.

The approved abbreviated new drug application (ANDA) is therapeutically equivalent to HZNP Medicines’ reference listed drug product Pennsaid Topical Solution, 2% w / w.

Health technology and data science firm IQVIA estimates that Diclofenac sodium topical solution USP, 2% w / w, has an estimated market size of $974m for twelve months ending December 2018.

Osteoarthritis is the most common form of arthritis, which affects several people globally. It occurs when flexible tissue at the end of bones wears down.

Osteoarthritis of the knee affects the bones, cartilage and synovium in the knee joint. It takes several years to develop and it progresses in stages.

India-based Alembic has a cumulative total of 109 ANDA approvals from the FDA; 96 are final approvals and 13 tentative approvals.

Alembic manufactures and markets generic pharmaceutical products worldwide. The company’s research and manufacturing facilities are approved by regulatory authorities of several developed countries, including the FDA.

Alembic has recently secured final approval from the FDA for its ANDA Silodosin Capsules, 4 mg and 8 mg. Silodosin capsule, a selective alpha1 adrenergic receptor antagonist, is indicated to treat the signs and symptoms of benign prostatic hyperplasia.

Latest stories

Related stories

Buyout of SpringWorks Brings Back Merck KGaA in the M&A Game

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally...

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The...

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back